Financhill
Sell
20

ATRA Quote, Financials, Valuation and Earnings

Last price:
$6.91
Seasonality move :
-15.4%
Day range:
$7.17 - $7.60
52-week range:
$5.40 - $20.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.42x
P/B ratio:
--
Volume:
49.9K
Avg. volume:
87.8K
1-year change:
-53.8%
Market cap:
$42M
Revenue:
$128.9M
EPS (TTM):
-$12.97

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ATRA
Atara Biotherapeutics
$16.6M -$3.49 -87.43% -61.97% $12.25
BMRA
Biomerica
-- -- -- -- --
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.33% $115.62
MRNA
Moderna
$941.1M -$2.73 -19.37% -0.05% $54.14
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
SWTX
SpringWorks Therapeutics
$60.5M -$0.71 218.64% -37.01% $72.88
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ATRA
Atara Biotherapeutics
$7.17 $12.25 $42M -- $0.00 0% 0.42x
BMRA
Biomerica
$0.70 -- $12.8M -- $0.00 0% 2.12x
BSX
Boston Scientific
$98.90 $115.62 $146B 79.12x $0.00 0% 8.78x
MRNA
Moderna
$34.71 $54.14 $13.4B -- $0.00 0% 4.21x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
SWTX
SpringWorks Therapeutics
$49.84 $72.88 $3.7B -- $0.00 0% 19.28x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ATRA
Atara Biotherapeutics
-- -0.649 -- 0.33x
BMRA
Biomerica
-- 1.014 -- 1.97x
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
MRNA
Moderna
-- 0.488 -- 3.45x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
SWTX
SpringWorks Therapeutics
-- 0.555 -- 3.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ATRA
Atara Biotherapeutics
$26M -$12.2M -2818.48% -2818.48% -35.71% -$24.6M
BMRA
Biomerica
$437K -$993K -81.84% -81.84% -60.7% -$824K
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
SWTX
SpringWorks Therapeutics
$56M -$81.3M -46.69% -46.69% -132.16% -$35.6M

Atara Biotherapeutics vs. Competitors

  • Which has Higher Returns ATRA or BMRA?

    Biomerica has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -58.07%. Atara Biotherapeutics's return on equity of -2818.48% beat Biomerica's return on equity of -81.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
    BMRA
    Biomerica
    26.71% -$0.06 $5.1M
  • What do Analysts Say About ATRA or BMRA?

    Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand Biomerica has an analysts' consensus of -- which suggests that it could grow by 1757.41%. Given that Biomerica has higher upside potential than Atara Biotherapeutics, analysts believe Biomerica is more attractive than Atara Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATRA
    Atara Biotherapeutics
    4 2 0
    BMRA
    Biomerica
    0 0 0
  • Is ATRA or BMRA More Risky?

    Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison Biomerica has a beta of -1.163, suggesting its less volatile than the S&P 500 by 216.324%.

  • Which is a Better Dividend Stock ATRA or BMRA?

    Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomerica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Biomerica pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATRA or BMRA?

    Atara Biotherapeutics quarterly revenues are $32.8M, which are larger than Biomerica quarterly revenues of $1.6M. Atara Biotherapeutics's net income of -$12.7M is lower than Biomerica's net income of -$950K. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Biomerica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 2.12x for Biomerica. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
    BMRA
    Biomerica
    2.12x -- $1.6M -$950K
  • Which has Higher Returns ATRA or BSX?

    Boston Scientific has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of 12.41%. Atara Biotherapeutics's return on equity of -2818.48% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
  • What do Analysts Say About ATRA or BSX?

    Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 16.91%. Given that Atara Biotherapeutics has higher upside potential than Boston Scientific, analysts believe Atara Biotherapeutics is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATRA
    Atara Biotherapeutics
    4 2 0
    BSX
    Boston Scientific
    23 4 0
  • Is ATRA or BSX More Risky?

    Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

  • Which is a Better Dividend Stock ATRA or BSX?

    Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATRA or BSX?

    Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Atara Biotherapeutics's net income of -$12.7M is lower than Boston Scientific's net income of $566M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 79.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 8.78x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
    BSX
    Boston Scientific
    8.78x 79.12x $4.6B $566M
  • Which has Higher Returns ATRA or MRNA?

    Moderna has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -117.16%. Atara Biotherapeutics's return on equity of -2818.48% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About ATRA or MRNA?

    Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand Moderna has an analysts' consensus of $54.14 which suggests that it could grow by 55.97%. Given that Atara Biotherapeutics has higher upside potential than Moderna, analysts believe Atara Biotherapeutics is more attractive than Moderna.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATRA
    Atara Biotherapeutics
    4 2 0
    MRNA
    Moderna
    5 17 1
  • Is ATRA or MRNA More Risky?

    Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

  • Which is a Better Dividend Stock ATRA or MRNA?

    Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATRA or MRNA?

    Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than Moderna quarterly revenues of $956M. Atara Biotherapeutics's net income of -$12.7M is higher than Moderna's net income of -$1.1B. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 4.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
    MRNA
    Moderna
    4.21x -- $956M -$1.1B
  • Which has Higher Returns ATRA or NBY?

    NovaBay Pharmaceuticals has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -49.65%. Atara Biotherapeutics's return on equity of -2818.48% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ATRA or NBY?

    Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Atara Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Atara Biotherapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATRA
    Atara Biotherapeutics
    4 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ATRA or NBY More Risky?

    Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock ATRA or NBY?

    Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATRA or NBY?

    Atara Biotherapeutics quarterly revenues are $32.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Atara Biotherapeutics's net income of -$12.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns ATRA or SWTX?

    SpringWorks Therapeutics has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -125.59%. Atara Biotherapeutics's return on equity of -2818.48% beat SpringWorks Therapeutics's return on equity of -46.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
  • What do Analysts Say About ATRA or SWTX?

    Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 46.22%. Given that Atara Biotherapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Atara Biotherapeutics is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATRA
    Atara Biotherapeutics
    4 2 0
    SWTX
    SpringWorks Therapeutics
    5 0 0
  • Is ATRA or SWTX More Risky?

    Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.323%.

  • Which is a Better Dividend Stock ATRA or SWTX?

    Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATRA or SWTX?

    Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than SpringWorks Therapeutics quarterly revenues of $61.5M. Atara Biotherapeutics's net income of -$12.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 19.28x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
    SWTX
    SpringWorks Therapeutics
    19.28x -- $61.5M -$77.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock